Management Forum Logo

Presented by
Management Forum

Pharmaceutical Regulatory Affairs in China Training Course

A detailed overview of the key areas of pharmaceutical regulatory affairs in China, Hong Kong, Macau and Taiwan.

★★★★★ "Very clear, interesting and worth it!"

25-26 June 2025
+ 26-27 November 2025 »
from £1299

Need help? Enrol/reserve

Format: Live online
CPD: 12 hours for your records
Certificate of completion

Course overview

This seminar will provide an invaluable overview of how to gain and maintain a successful pharmaceutical marketing authorisation in the People’s Republic of China (PRC), including Hong Kong, Macau and Taiwan.The two-day course will cover:

• All important aspects of gaining and maintaining a successful marketing authorisation in the region
• Recent regulatory reforms
• Drug regulatory systems
• An overview of import and local manufacture registration
• Clinical product development including CMC regulatory requirements
• An interpretation of practical aspects
• The opportunity to exchange experiences with other delegates

Benefits of attending:

Gain an overview of the regulatory procedures in the region
Understand and assess the impact of recent regulatory reforms
Discuss clinical product development and Chinese-specific approaches
Understand requirements for import and local manufacture registration
Discuss product registration strategies

This course is part of our Regulatory Affairs Training course collection, which features updates on the latest regulations to registration procedures and strategies.

Who should attend?

This seminar will be of particular interest to all those who need to learn about successful marketing authorisation applications and in-market regulatory compliance in this region. You will find this seminar useful both as an introductory or refresher course.

Previous delegates have included scientists and technical staff in regulatory affairs and registration departments, medical directors, and personnel from analytical research and development, clinical development, quality assurance, new business development and regulatory authorities.

Enrol/reserve

This course will cover:

Day 1
Day 2

General introduction to the PRC and the pharmaceutical market

Commercial and cultural background

P.R. China - Drug Regulatory Systems

Regulatory authorities
Recent regulatory changes
Regulations and guidelines
Drug classification systems
Import and local manufacture registration
Data requirements
Registration requirements
Labelling requirements

P.R. China - Clinical Product Development

Regulatory aspects of clinical development
Recent regulatory changes
Documentation needs including CMC
Regulatory requirements including GCP aspects
Chinese-specific approaches
Multinational clinical trials

Hong Kong SAR

Background overview
Regulatory authorities
Regulatory requirements and procedures
Specific market aspects

Macau SAR

Brief overview of regulatory aspects

P.R. China - Regulatory Strategies

P.R. China - Health Authority Interactions

P.R. China - Maintenance

Taiwan (Republic of China)

Cultural background
Regulatory authorities
Regulations and guidelines
Drug classification systems
Data requirements
Country-specific matters

P.R China - Recent Developments

Enrol/reserve

Alan Chalmers
Pharma International

Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs. A graduate of Strathclyde University in Glasgow with a B.Sc. in Pharmacy with specialisation in Pharmaceutical Technology, his Ph.D. at Manchester University was in Pharmaceutical Formulation. From 1975-1978 he was Development Officer and Clinical Trials Pharmacist of Allen & Hanburys (part of the then Glaxo group). In 1978 he joined Ciba-Geigy in DRA. Over 20 years were spent with Ciba-Geigy/CIBA/Novartis in all aspects of regulatory affairs including head of a group company DRA in Canada and for many years as Head of Pharma International regulatory affairs.

He has been consultant to the IFPMA, WHO and other international bodies and was Chairman of the Organising Committee of the initial IFPMA Asian Regulatory Conferences in Hong Kong and Singapore and Rapporteur to the more recent conferences in China and Malaysia.

Since 1998 he has been an independent regulatory consultant and is Director of his own consultancy company Pharma International in Switzerland. He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy. More recently as accredited by Swissmedic, Dr. Chalmers is a Qualified Person supporting several Swiss pharmaceutical companies trading internationally with pharmaceuticals and medical devices.

He is published, and his publications include a textbook on International Pharmaceutical Registration, Active Pharmaceutical Ingredients and as Swiss correspondent to the Regulatory Affairs Journals Pharma and Medtech. Since 2012 he has been a member of the Editorial Board, Scrip Regulatory Affairs.

More details

Monica Dressler-Meyer
Pharma International

Mónica Dressler-Meyer is DRA Manager based in Switzerland with many years of regulatory experience. She has spent many years in DRA working with different pharmaceutical companies with responsibility for Asia Pacific and lately also for development activities in other regions. Prior to this, she worked at F. Hoffmann-La Roche in Switzerland where she gained several years’ experience in industry basics and pre-clinical research. She has a Degree in Chemistry and Biochemistry from Basel University.

More details

NEW higher discounts for multiple bookings - bring your colleagues to make your training budget go further:

30% off the 2nd delegate*
40% off the 3rd delegate*
50% off the 4th delegate*

Please contact us for pricing if you are interested in booking 5 or more delegates

25-26 June 2025

Live online

09:00-17:00 UK (London) (UTC+01)
10:00-18:00 Paris (UTC+02)
04:00-12:00 New York (UTC-04)
Course code 14793

GBP 1,499
EUR 2,099
USD 2,399

2 days live online training
Browser-based, no download usually required
See presenters and interact with fellow attendees
Download documentation and certification of completion
Fair transfer and cancellation policy

View basket

Not ready to book yet?

for 7 days, no obligation

26-27 November 2025

Live online

09:00-17:00 UK (London) (UTC+00)
10:00-18:00 Paris (UTC+01)
04:00-12:00 New York (UTC-05)
Course code 15142

GBP 1,299 1,499
EUR 1,819 2,099
USD 2,087 2,399

Until 22 Oct

2 days live online training
Browser-based, no download usually required
See presenters and interact with fellow attendees
Download documentation and certification of completion
Fair transfer and cancellation policy

View basket

Not ready to book yet?

for 7 days, no obligation

* Early booking discounts may not be combined with other discounts or offers. As such, the discounts for 2nd/3rd/4th delegates are based on the full price; and apply only when booking multiple delegates on the same date.

Reviews of IPI's Pharmaceutical Regulatory Affairs in China training course

Very clear, interesting and worth it!

Apr 29 2024

Mélissa Cardenas Trujillo France
Regulatory Affairs & Registrations Specialist I, Laboratoires Thea Sas

Dec 10 2024

Valuable Webinar and very good interactions with the speakers.

Celine Aubertin France
International Regulatory Affairs Manager, NOOUS FINANCE AU NOM ET POUR LE COMPTE DE PIERRE FABRE SA

Dec 12 2023

The content are useful for my purpose, I receive additional and detailed information. The presentation and speakers are very clear.

Adriana Merlicco Italy
Regulatory, Alfasigma S.p.A.

Nov 22 2022

I would highly recommend [...] I appreciate there were more than one speaker to change it up and make the different topics more varied to listen in on. Also very nice how the speakers would supplement each other when responding to questions

Maria Mikkelsen Denmark
Regulatory CMC Specialist, Ascendis Pharma

Nov 22 2022

I would highly recommend

Maria Mikkelsen Denmark
Regulatory CMC Specialist, Ascendis Pharma

Nov 25 2020

The speakers were very professional, detailed in providing information and they promoted interactions/questions in order to try to deepen together the topics covered.

Teresa Bruno Italy
Regulatory Affairs Officer, Menarini Ricerche Spa

Nov 25 2020

Good rhythm with 2 speakers. Good and clear presentations. Interactive course.

Nadège Caminet Switzerland
Director QA Immunology (CH) / Responsible Person, Swedish Orphan Biovitrum

Nov 25 2020

The speakers were very helpful and supportive in answering any questions.

Rand Qeshta Ireland
Regulatory Affairs Manager , Recordati Ireland

Nov 20 2019

Both presentations were well prepared and presented and Alan and Monica answered further questions.

Julia Strack Germany
Manager Regulatory Affairs, Cheplapharm Arzneimittel GmbH

Nov 20 2019

Super programme, super speakers!

Lu Dao Germany
Manager Regulatory Affairs, Cheplapharm Arzneimittel GmbH

Nov 20 2019

Overall, a very informative introduction to regulatory affairs in Greater China.

Chek Ing (Agnes) Kiu Weber Switzerland
CEO, AiGenix Life Science Consulting GmbH

Nov 20 2019

The course is really interesting and the small group allowed good interactions with the speakers and between the participants.

Céline Anselmetti Switzerland
Debiopharm Research & Manufacturing SA

Nov 27 2018

Excellent Speakers, helpful discussions during the sessions & coffee breaks

Thorben Bonarius Switzerland
Global Head Regulatory Affairs, Siegfried AG

Nov 27 2018

The course was good with a lot of valuable information.

Robert Klasson Denmark
Manager Regulatory Affairs API, Xellia Pharmaceuticals ApS

Nov 27 2018

Both are really great speakers.

Nermin Ipek Denmark
Regulatory Affairs Team Leader, Novo Nordisk

Nov 27 2018

Very good. Speakers with great experience.

Mauro Catena Switzerland
Manager, Helsinn Healthcare SA

Nov 21 2017

Great

Mia Kiistala United States of America
Senior Manager, Biogen

Nov 21 2017

This course was well paced and met my needs in terms of content and interactivity. Both speakers were extremely knowledgeable and approachable which is I believe is important in this setting.

Chris Dodd United Kingdom
Medical Regulatory Manager, Mexichem UK Ltd